Skip to main content
SpringerLink
Log in

Tumeurs stromales gastro-intestinales (GIST)

  • Chapter
Tumeurs malignes rares

  • 62 Accesses

Résumé

Les tumeurs stromales gastro-intestinales (GIST) n’étaient pas reconnues comme des entités cliniques distinctes en 1998, bien que plusieurs équipes d’anatomopathologistes aient rapporté depuis 1983 leur existence et leurs particularités phénotypiques en les désignant sous différents noms (GIST, GANT, GIPACT, ICCT…) (1). En 2009, dix ans après, cette tumeur est devenue le paradigme des maladies néoplasiques traitées par des thérapeutiques ciblées et les règles de leur prise en charge, toujours en rapide évolution, semblent pouvoir s’appliquer à des tumeurs plus fréquentes au-delà des sarcomes.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Références

  1. Mazur MT, Clark HB (1983) Gastric stromal tumors. Reappraisal of histogenesis. Am J Surg Pathol 7: 507–19

    Article  CAS  PubMed  Google Scholar 

  2. Corless CL, Fletcher JA, Heinrich MC (2004) Biology of gastrointestinal stromal tumors. J Clin Oncol 22: 3813–25

    Article  CAS  PubMed  Google Scholar 

  3. Nilsson B, Bumming P, Meis-Kindblom JM, et al. (2005) Gastrointestinal stromal tumors: the incidence, prevalence, clinical course, and prognostication in the preimatinib mesylate era—a population-based study in western Sweden. Cancer 103: 821–9

    Article  PubMed  Google Scholar 

  4. Ducimetière F, Lurkin A, Ranchere D, et al. (2008) Prospective incidence of sarcoma after systematic review of pathological diagnosis: new findings. Proceeding of the CTOS 14th meeting (abstract)

    Google Scholar 

  5. Agaimy A, Wunsch PH, Hofstaedter F, et al. (2007) Minute gastric sclerosing stromal tumors (GIST tumorlets) are common in adults and frequently show c-KIT mutations. Am J Surg Pathol 31: 113–20

    Article  PubMed  Google Scholar 

  6. Hirota S, Isozaki K, Moriyama Y, et al. (1998) Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science 279: 577–80

    Article  CAS  PubMed  Google Scholar 

  7. Heinrich MC, Corless CL, Demetri GD, et al. (2003) Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol 21: 4342–9

    Article  CAS  PubMed  Google Scholar 

  8. Rubin BP, Antonescu CR, Scott-Browne JP, et al. (2005) A knock-in mouse model of gastrointestinal stromal tumor harboring kit K641E. Cancer Res 65: 6631–9

    Article  CAS  PubMed  Google Scholar 

  9. Godwin AK, Rink L, Chi T, et al. (2008) Insulin-like growth factor 1 receptor (IGF-1R): A potential therapeutic target for gastrointestinal stromal tumors (GIST). J Clin Oncol 26; Abstract and slides 10507

    Google Scholar 

  10. Blay JY, Bonvalot S, Casali P, et al. (2005) GIST consensus meeting panelists. Consensus meeting for the management of gastrointestinal stromal tumors. Report of the GIST Consensus Conference of 20–21 March 2004, under the auspices of ESMO. Ann Oncol 16: 566–78

    Article  PubMed  Google Scholar 

  11. Demetri G, Benjamin R, Blanke CD (2006) NCCN risk force report: optimal management of patients with gastrointestinal stromal tumors (GIST). Expansion and Update of NCCN Clinical Practice Guidelines. J Natl Compr Cancer Netw 2: S1–S26

    Google Scholar 

  12. Casali PG, Jost L, Reichardt P, et al. (2008) ESMO Guidelines Working Group. Gastrointestinal stromal tumors: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 19: ii35–8

    Google Scholar 

  13. Fletcher CD, Berman JJ, Corless C, et al. (2002) Diagnosis of gastrointestinal stromal tumors: A consensus approach. Hum Pathol 33: 459–65

    Article  PubMed  Google Scholar 

  14. Miettinen M, Lasota J (2006) Gastrointestinal stromal tumors: pathology and prognosis at different sites. Semin Diagn Pathol 23: 70–83

    Article  PubMed  Google Scholar 

  15. Demetri GD, von Mehren M, Blanke CD, et al. (2002) Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 347: 472–80

    Article  CAS  PubMed  Google Scholar 

  16. Verweij J, Casali PG, Zalcberg J, et al. (2004) Progression-free survival in gastrointestinal stromal tumours with highdose imatinib: randomised trial. Lancet 364: 1127–34

    Article  CAS  PubMed  Google Scholar 

  17. Blanke CD, Rankin C, Demetri GD, et al. (2008) Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033. J Clin Oncol 26: 626–32

    Article  CAS  PubMed  Google Scholar 

  18. Van Glabbeke MM, Owzar K, Rankin C, et al. and the GIST Meta-analysis Group (MetaGIST) (2007) Comparison of two doses of imatinib for the treatment of unresectable or metastatic gastrointestinal stromal tumors (GIST): A metaanalyis based on 1,640 patients (pts). Journal of Clinical Oncology, ASCO Annual Meeting Proceedings 25: 10004

    Google Scholar 

  19. Heinrich MC, Corless CL, Blanke CD, et al. (2006) Molecular Correlates of Imatinib Resistance in Gastrointestinal Stromal Tumors. J Clin Oncol 24: 4764–74

    Article  CAS  PubMed  Google Scholar 

  20. Debiec-Rychter M, Sciot R, Le CA, et al. (2006) KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours. Eur J Cancer 42: 1093–103

    Article  CAS  PubMed  Google Scholar 

  21. Blay JY, Le Cesne A, Ray-Coquard I, et al. (2007) Prospective multicentric randomized phase III study of imatinib in patients with advanced gastrointestinal stromal tumors comparing interruption versus continuation of treatment beyond 1 year: the French Sarcoma Group. J Clin Oncol 25: 1107–13

    Article  CAS  PubMed  Google Scholar 

  22. Benjamin RS, Choi H, Macapinlac HA, et al. (2007) We should desist using RECIST, at least in GIST. J Clin Oncol 25: 1760–4

    Article  PubMed  Google Scholar 

  23. De Matteo R, Owzar K, Maki R, et al. (2007) Adjuvant imatinib mesylate increases recurrence free survival (RFS) in patients with completely resected localized primary gastrointestinal stromal tumor (GIST): North American Intergroup Phase III trial ACOSOG Z9001. J Clin Oncol ASCO Ann Meet Proc Part I. Vol 25, no 18S, 10079

    Google Scholar 

  24. Hohenberger P, Langer C, Pistorius S, et al. (2006) Indication and results of surgery following imatinib treatment of locally advanced or metastatic GI stromal tumors (GIST). J Clin Oncol (Meeting Abstracts) 24: 9500

    Google Scholar 

  25. Raut CP, Posner M, Desai J, et al. (2006) Surgical management of advanced gastrointestinal stromal tumors after treatment with targeted systemic therapy using kinase inhibitors. J Clin Oncol 24: 2325–31

    Article  CAS  PubMed  Google Scholar 

  26. Bonvalot S (2008) An update of the surgical indications for gastrointestinal stromal tumors J Chir 145: 6S8–11

    Article  Google Scholar 

  27. Zalcberg JR, Verveij J, Casali PG, et al. (2005) Outcome of patients with advanced gastro-intestinal stromal tumours crossing over to a daily imatinib dose of 800 mg after progression on 400 mg. Eur J Cancer 41: 1751–7

    Article  CAS  PubMed  Google Scholar 

  28. Atkins M, Jones CA, Kirkpatrick P (2006) Sunitinib maleate. Nat Rev Drug Discov 5: 279–80

    Article  CAS  PubMed  Google Scholar 

  29. Demetri GD, van Oosterom AT, Garrett CR, et al. (2006) Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet 368: 1329–38

    Article  CAS  PubMed  Google Scholar 

  30. George S, Blay JY, Casali PG, et al. (2008) Continuous daily dosing (CDD) of sunitinib (SU) in pts with advanced GIST: Updated efficacy, safety, PK and pharmacodynamic analysis. J Clin Oncol 26, abstract 10554

    Google Scholar 

  31. Heinrich MC, Maki RG, Corless CL, et al. (2008) Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib malate in imatinib-resistant. J Clin Oncol e-pub ahead of print: doi/10.1200/JCO.2007.15.7461

    Google Scholar 

  32. Benjamin R, Schöffski P, Hartmann JT, et al. (2006) Initial results of a multicenter single arm phase 2 study of AMG 706, an oral multi-kinase inhibitor, for the treatment of advanced imatinib-resistant gastrointestinal stromal tumors (GIST). 12th Annual CTOS Meeting, Venice November 2–4 (abst 618)

    Google Scholar 

  33. Blay JY, Casali PG, Reichardt P, et al. (2008) A phase I study of nilotinib alone and in combination with imatinib in patients with imatinib-resistant gastrointestinal stromal tumors (GIST): Study update. J Clin Oncol 26; Abstract 10553

    Google Scholar 

  34. Reichardt P, Pink D, Lindner T, et al. (2005) A phase I/II trial of the oral PKC-inhibitor PKC412 (PKC) in combination with imatinib mesylate (IM) in patients (pts) with gastrointestinal stromal tumor (GIST) refractory to IM. J Clin Oncol 23; Abstract 3016

    Article  Google Scholar 

  35. Joensuu H, De BF, Coco P, et al. (2006) A phase II, open-label study of PTK787/ZK222584 in the treatment of metastatic gastrointestinal stromal tumors (GISTs) resistant to imatinib mesylate. J Clin Oncol (Meeting Abstracts) 24 (18 suppl): 9531

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Département d’oncologie médicale, 28, rue Laennec, 39008, Lyon

    I. Ray-Coquard

  2. Équipe Cytokines et Cancer Unité INSERM 590 Conticanet Network of Excellence FP6-018806 Service d’oncologie médicale, pavillon E, Hôpital Edouard-Herriot Hospices civils de Lyon, Place d’Arsonval, 69437, Lyon Cedex 03

    P. Cassier

  3. Equipe Cytokines et Cancer Unité INSERM 590 Conticanet Network of Excellence FP6-018806 Oncogenèse et progression tumorale, Centre Léon-Bérard, 28, rue Laënnec, 69373, Lyon Cedex 08

    H. El Sayadi

  4. Département de cancérologie médicale Équipe Cytokines et Cancer Unité INSERM 590 Conticanet Network of Excellence FP6-018806 Service d’oncologie médicale, pavillon E, Hôpital Edouard-Herriot, Place d’Arsonval, 69437, Lyon Cedex 03

    J.-Y. Blay

  5. Centre Léon-Bérard, Université Claude-Bernard-Lyon I, 28, rue Laënnec, 69008, Lyon

    J.-Y. Blay

Authors
  1. I. Ray-Coquard
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. P. Cassier
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. H. El Sayadi
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. J.-Y. Blay
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

Copyright information

© 2010 Springer-Verlag France, Paris

About this chapter

Cite this chapter

Ray-Coquard, I., Cassier, P., El Sayadi, H., Blay, JY. (2010). Tumeurs stromales gastro-intestinales (GIST). In: Tumeurs malignes rares. Springer, Paris. https://doi.org/10.1007/978-2-287-72070-3_26

Download citation

  • DOI: https://doi.org/10.1007/978-2-287-72070-3_26

  • Publisher Name: Springer, Paris

  • Print ISBN: 978-2-287-72069-7

  • Online ISBN: 978-2-287-72070-3

Publish with us

Policies and ethics

Search

Navigation